Invivogen
Menu

Zeocin™

Zeocin™ (solution) Unit size Cat. code Docs Qty Price
Selective antibiotic for the Sh ble gene
500 mg (5 x 1ml)
1g (10 x 1 ml)
5g (50 x 1 ml)
5 g (50 ml bottle)
ant-zn-05
+-
$148.00
Zeocin™ (powder) Unit size Cat. code Docs Qty Price
Selective antibiotic for the Sh ble gene
1 g (powder)
5 g (powder)
ant-zn-1p
+-
$177.00

You may also need : Phleomycin | View more associated products

Zeocin™ | Selection antibiotic: cell culture tested, sterile reagent

InvivoGen is the sole worldwide producer of Zeocin™.

Zeocin™ is a formulation of phleomycin D1, a copper-chelated glycopeptide antibiotic produced by Streptomyces CL990. Zeocin™ causes cell death by intercalating into DNA and cleaving it.
The action of Zeocin™ is effective on most aerobic cells. Therefore, Zeocin™ is a popular and effective antibiotic for the selection of vectors bearing the Sh ble gene in a variety of cells types (bacteria, eukaryotic microorganisms, plant and animal cells).

Resistance to Zeocin™ is conferred by the Sh ble gene product from Streptoalloteichus hindustanus, which inactivates Zeocin™ upon binding to the antibiotic [1-3].
Sh ble is a small 370bp-sized gene and is carried in a number of InvivoGen’s vectors.

Typically, mammalian cells are sensitive to Zeocin™ concentrations of 50-400 µg/ml, and bacteria to 25 µg/ml.

 

References:

1. Drocourt D. et al., 1990. Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucl. Acids. Res. 18: 4009.
2. Gatignol A. et al., 1988. FEBS Letters. 230: 171-5.
3. Dumas P. et al., 1994. Embo J. 242 (5) 595-601.

Figures

Zeocin™ by InvivoGen
Zeocin™ by InvivoGen
Back to the top

Specifications

Product concentration: 100 mg/ml in solution

CAS number: 11006-33-0

Quality Control: Each lot is thoroughly tested to ensure the absence of lot-to-lot variation.

Endotoxin level: < 1 EU/mg

Physicochemical characterization: HPLC, pH, appearance

Cell-culture tested: potency validated in Zeocin™-sensitive and Zeocin™-resistant mammalian cell lines

Non-cytotoxicity of trace contaminants: absence of long-term effects confirmed in Zeocin™-resistant cells

Back to the top

Contents

Zeocin™ is supplied as a sterile filtered blue solution at 100 mg/ml in HEPES buffer.

This product is available in three pack sizes:

  • ant-zn-1: 10 x 1 ml (1 g)
  • ant-zn-5: 50 x 1 ml (5 g)
  • ant-zn-5b: 1 x 50 ml (5 g)

Zeocin™ is also supplied as a blue powder:

  • ant-zn-1p: 1 x 1 g
  • ant-zn-5p: 1 x 5 g

Zeocin™ is shipped at room temperature.

Upon receipt it should be stored at 4°C or -20°C.

Zeocin™ is a harmful compound. Refer to safety data sheet for handling instructions.

Back to the top

Details

WORKING CONCENTRATIONS

Zeocin™ is normally used at a concentration of 100 μg/ml, a 1000-fold dilution from the stock solution. However, the optimal concentration needs to be determined for your cells.
Suggested concentrations of Zeocin™ for selection in some examples of mammalian cells are listed below:

Cell line

Medium

Zeocin™ conc

References

B16 (Mouse melanocytes)

RPMI

20-250 μg/ml

1-3

CHO (Chinese hamster ovarian cells)

DMEM

100-500 μg/ml

1, 4, 5

COS (Monkey kidney cells)

DMEM

100-400 μg/ml

6, 7

HEK293 (Human embryonic kidney cells) DMEM 100-400 μg/ml 8, 9
HeLa (Human uterine cells) DMEM 50-100 μg/ml 10, 11
J558L (Mouse melanocytes) RPMI 400 μg/ml 12
MCF-7 (Human breast adenocarcinoma cells) DMEM 100-400 μg/ml 13, 14
MEFs (Mouse embryonic fibroblasts) DMEM 200-400 μg/ml 15, 16
THP-1 (Human monocytes) RPMI 200 μg/ml 17

References:

1. Bouayadi K. et al., 1997. Overexpression of DNA polymerase beta sensitizes mammalian cells to 2’,3’ deoxycytidine and 3’-azido-3’-deoxythymidine. Cancer Res. 57: 110-116.
2 Hirose Y. et al., 2012. Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. PNAS, 109: 4263 - 4268.
3. Fan H. et al., 2012. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res.18(20):5628-38.
4. Li F. et al., 1996. Post-translational modifications of recombinant P-selection glycoprotein ligand-1 required for binding to P- and E- selection. J. Biol. Chem. 271: 3255-3264.
5.  Ogura  T.  et al., 2004. Resistance of B16 melanoma cells to CD47-induced negative regulation of motility as a result of aberrant N-glycosylation of SHPS-1. J Biol Chem. 279(14):13711-20.
6. Saxena A. et al., 2002. H2, the minor subunit of the human asialoglycoprotein receptor, trafficks intracellularly and forms homo-oligomers, but does not bind asialo-orosomucoid. J Biol Chem. 277(38):35297-304.
7. Kanamori A. et al., 2002. Distinct sulfation requirements of selectins disclosed using cells that support rolling mediated by all three selectins under shear flow. L-selectin prefers carbohydrate 6-sulfation totyrosine sulfation, whereas p-selectin does not. J Biol Chem. 277(36):32578-86.
8. Ahmed et al., 2013. TRIF-mediated TLR3 and TLR4 signaling is negatively regulated by ADAM15. J Immunol. 190(5):2217-28.
9. Büllesbach EE. & Schwabe C., 2006. The mode of interaction of the relaxin-like factor (RLF) with the leucine-rich repeat G protein-activated receptor 8. J Biol Chem. 281(36):26136-43.
10. Mesnil M. et al., 1996. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. PNAS 93(5):1831-5.
11. Maszczak-Seneczko D. et al., 2013. UDP-N-acetylglucosamine transporter (SLC35A3) regulates biosynthesis of highly branched N-glycans and keratan sulfate. J Biol Chem. 288(30):21850-60.
12. Cedeno-Laurent F. et al., 2010. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol. 185(8):4659-72.
13. Kim HS. et al., 2004. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 64(6):2229-37.
14. List HJ. et al., 2001. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem. 276(26):23763-8.
15. Waak J. et al., 2009. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1. J Biol Chem. 284(21):14245-57.
16. MacDonald M. et al., 2007. The zinc finger antiviral protein acts synergistically with an interferon-induced factor for maximal activity against alphaviruses. J Virol. 81(24):13509-18.
17. Maue A. et al., 2013. The polysaccharide capsule of Campylobacter jejuni modulates the host immune response. Infect Immun. 81(3):665-72

Back to the top

Citations

Load more
Customer Service
& Technical Support
Shopping cart is empty